By Daniella Parra
Jeito Capital said it invested in Callio Therapeutics’ $187M Series A round to support its next-generation multi-payload antibody-drug conjugates (ADCs) for cancer treatment.
Callio Therapeutics is a biotechnology company developing multi-payload ADCs that says it aims to overcome resistance mechanisms in oncology.
“We are pleased to support Callio Therapeutics as it advances its differentiated multi-payload ADC platform to address some of the biggest challenges in oncology,” Dr Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital said. “As long-standing investors in this therapeutic area, we recognize the quality and potential of Callio’s approach to overcome resistance mechanisms and improve outcomes for patients with hard-to-treat cancers.”
Contact:
